Systemic CD4 Immunity and PD-L1/PD-1 Blockade Immunotherapy

被引：12

作者：

Escors, David ^{[1
]}

Bocanegra, Ana ^{[1
]}

Chocarro, Luisa ^{[1
]}

Blanco, Ester ^{[1
]}

Pineiro-Hermida, Sergio ^{[1
]}

Garnica, Maider ^{[1
]}

Fernandez-Rubio, Leticia ^{[1
]}

Vera, Ruth ^{[2
]}

Arasanz, Hugo ^{[1
,2
]}

Kochan, Grazyna ^{[1
]}

机构：

[1] UPNA, Oncoimmunol Grp, Navarrabiomed,Hosp Univ Navarra, Fdn Miguel Servet,IdISNA, Irunlarrea 3, Pamplona 31008, Spain

[2] Hosp Univ Navarra, Dept Med Oncol, IdISNA, Irunlarrea 3, Pamplona 31008, Spain

来源：

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | 2022年 / 23卷 / 21期

关键词：

T lymphocytes; immune checkpoint; biomarker; REGULATORY T-CELLS; ANTIGEN-PRESENTING CELLS; DENDRITIC CELLS; PD-1; BLOCKADE; CHECKPOINT BLOCKADE; PERIPHERAL-BLOOD; LYMPHOCYTE RATIO; CANCER-PATIENTS; TH17; CELLS; NEGATIVE REGULATION;

D O I：

10.3390/ijms232113241

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

PD-L1/PD-1 blockade immunotherapy has changed the therapeutic approaches for the treatment of many cancers. Nevertheless, the mechanisms underlying its efficacy or treatment failure are still unclear. Proficient systemic immunity seems to be a prerequisite for efficacy, as recently shown in patients and in mouse models. It is widely accepted that expansion of anti-tumor CD8 T cell populations is principally responsible for anti-tumor responses. In contrast, the role of CD4 T cells has been less studied. Here we review and discuss the evidence supporting the contribution of CD4 T cells to anti-tumor immunity, especially recent advances linking CD4 T cell subsets to efficacious PD-L1/PD-1 blockade immunotherapy. We also discuss the role of CD4 T cell memory subsets present in peripheral blood before the start of immunotherapies, and their utility as predictors of response.

引用

页数：19

共 191 条

[11] Expression of PD-1/PD-L1 and PD-L2 in peripheral T-cells from non-small cell lung cancer patients [J].

Arrieta, Oscar ;

Montes-Servin, Edgar ;

Hernandez-Martinez, Juan-Manuel ;

Cardona, Andres F. ;

Casas-Ruiz, Eibar ;

Crispin, Jose C. ;

Motola, Daniel ;

Flores-Estrada, Diana ;

Barrera, Lourdes .

ONCOTARGET, 2017, 8 (60) :101994-102005

[12] Initial efficacy of anti-lymphocyte activation gene-3 (anti-LAG-3; BMS-986016) in combination with nivolumab (nivo) in pts with melanoma (MEL) previously treated with anti-PD-1/PD-L1 therapy. [J].

Ascierto, Paolo Antonio ;

Melero, Ignacio ;

Bhatia, Shailender ;

Bono, Petri ;

Sanborn, Rachel E. ;

Lipson, Evan J. ;

Callahan, Margaret K. ;

Gajewski, Thomas ;

Gomez-Roca, Carlos A. ;

Hodi, F. Stephen ;

Curigliano, Giuseppe ;

Nyakas, Marta ;

Preusser, Matthias ;

Koguchi, Yoshinobu ;

Maurer, Matthew ;

Clynes, Raphael ;

Mitra, Priyam ;

Suryawanshi, Satyendra ;

Munoz-Couselo, Eva .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35

[13] B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells [J].

Azuma, Takeshi ;

Yao, Sheng ;

Zhu, Gefeng ;

Flies, Andrew S. ;

Flies, Sarah J. ;

Chen, Lieping .

BLOOD, 2008, 111 (07) :3635-3643

[14] Negative regulation of lymphocyte activation and autoimmunity by the molecular adaptor Cbl-b [J].

Bachmaier, K ;

Krawczyk, C ;

Kozieradzki, I ;

Kong, YY ;

Sasaki, T ;

Oliveira-dos-Santos, A ;

Mariathasan, S ;

Bouchard, D ;

Wakeham, A ;

Itie, A ;

Le, J ;

Ohashi, PS ;

Sarosi, I ;

Nishina, H ;

Lipkowitz, S ;

Penninger, JM .

NATURE, 2000, 403 (6766) :211-216

[15] Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer [J].

Bagley, Stephen J. ;

Kothari, Shawn ;

Aggarwal, Charu ;

Bauml, Joshua M. ;

Alley, Evan W. ;

Evans, Tracey L. ;

Kosteva, John A. ;

Ciunci, Christine A. ;

Gabriel, Peter E. ;

Thompson, Jeffrey C. ;

Stonehouse-Lee, Susan ;

Sherry, Victoria E. ;

Gilbert, Elizabeth ;

Eaby-Sandy, Beth ;

Mutale, Faith ;

DiLullo, Gloria ;

Cohen, Roger B. ;

Vachani, Anil ;

Langer, Corey J. .

LUNG CANCER, 2017, 106 :1-7

[16] Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse [J].

Bates, Gaynor J. ;

Fox, Stephen B. ;

Han, Cheng ;

Leek, Russell D. ;

Garcia, Jose F. ;

Harris, Adrian L. ;

Banham, Alison H. .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (34) :5373-5380

[17] Induction of a CD8(+) cytotoxic T lymphocyte response by cross-priming requires cognate CD4(+) T cell help [J].

Bennett, SRM ;

Carbone, FR ;

Karamalis, F ;

Miller, JFAP ;

Heath, WR .

JOURNAL OF EXPERIMENTAL MEDICINE, 1997, 186 (01) :65-70

[18] Association Between Pretreatment Neutrophil-to-Lymphocyte Ratio and Outcome of Patients With Metastatic Renal-Cell Carcinoma Treated With Nivolumab [J].

Bilen, Mehmet Asim ;

Dutcher, Giselle Marie Almeida ;

Liu, Yuan ;

Ravindranathan, Deepak ;

Kissick, Haydn T. ;

Carthon, Bradley C. ;

Kucuk, Omer ;

Harris, Wayne B. ;

Master, Viraj A. .

CLINICAL GENITOURINARY CANCER, 2018, 16 (03) :E563-E575

[19]

Bocanegra A, 2022, medRxiv, DOI [10.1101/2022.06.16.22276511, 10.1101/2022.06.16.22276511, DOI 10.1101/2022.06.16.22276511]

[20] PD-L1 Expression in Systemic Immune Cell Populations as a Potential Predictive Biomarker of Responses to PD-L1/PD-1 Blockade Therapy in Lung Cancer [J].

Bocanegra, Ana ;

Fernandez-Hinojal, Gonzalo ;

Zuazo-Ibarra, Miren ;

Arasanz, Hugo ;

Jesus Garcia-Granda, Maria ;

Hernandez, Carlos ;

Ibanez, Maria ;

Hernandez-Marin, Berta ;

Martinez-Aguillo, Maite ;

Jose Lecumberri, Maria ;

Fernandez de Lascoiti, Angela ;

Teijeira, Lucia ;

Morilla, Idoia ;

Vera, Ruth ;

Escors, David ;

Kochan, Grazyna .

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (07)

← 1 2 3 4 5 6 7 8 9 10 →